Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it
Yuanyuan Wang, Jiyuan Chen, Zhengjie Wu, et al.
British Journal of Pharmacology (2020) Vol. 178, Iss. 2, pp. 239-261
Open Access | Times Cited: 82

Showing 26-50 of 82 citing articles:

The epigenetic function of androgen receptor in prostate cancer progression
Takahiro Sawada, Yoshiaki Kanemoto, Tomohiro Kurokawa, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 8
Role of exosomes in prostate cancer and male fertility
Dwaipayan Dey, Srestha Ghosh, Divya Mirgh, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103791-103791
Closed Access | Times Cited: 8
Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
Javier Pozas, Sara Álvarez Rodríguez, Víctor Albarrán, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6071-6071
Open Access | Times Cited: 13
Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancer
Huihui Fan, Jinze Li, Astrid M. Manuel, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 31, pp. 648-661
Open Access | Times Cited: 7
Combination of miR-99b-5p and Enzalutamide or Abiraterone Synergizes the Suppression of EMT-Mediated Metastasis in Prostate Cancer
Mohammad Waseem, Bi‐Dar Wang
Cancers (2024) Vol. 16, Iss. 10, pp. 1933-1933
Open Access | Times Cited: 2
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer
Bo Chen, Pengfei Xu, Joy C. Yang, et al.
Oncogene (2024) Vol. 43, Iss. 30, pp. 2325-2337
Open Access | Times Cited: 2
RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression
Tingting Zhou, Shengli Wang, Xiaoyu Song, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 11
Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis
Yue Gu, Mengxia Xue, Qizhi Wang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13222-13222
Open Access | Times Cited: 15
KCa1.1 K+ Channel Inhibition Overcomes Resistance to Antiandrogens and Doxorubicin in a Human Prostate Cancer LNCaP Spheroid Model
Susumu Ohya, Junko Kajikuri, Kyoko Endo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13553-13553
Open Access | Times Cited: 13
Polyethylene glycol-modified mesoporous polydopamine nanoparticles co-loaded with dimethylcurcumin and indocyanine green for combination therapy of castration-resistant prostate cancer
Jun Hong, Ya-Ting Tang, Mengting Zhou, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 69, pp. 103158-103158
Closed Access | Times Cited: 9
Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer
Suman Mazumder, Taraswi Mitra Ghosh, Ujjal Kumar Mukherjee, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 6009-6009
Open Access | Times Cited: 9
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 7, pp. 1286-1311
Open Access | Times Cited: 5
Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer
Madhuvanthi Giridharan, Vasu Rupani, Satarupa Banerjee
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 4, pp. 193-206
Open Access | Times Cited: 8
Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer
Junhua Li, Run Zhu, Xiaoxi Zhuang, et al.
Bioorganic Chemistry (2023) Vol. 135, pp. 106495-106495
Closed Access | Times Cited: 4
Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
Yuezheng Li, Haoyu Wang, Yang Pan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 4
Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study
Rahma Said, Javier Hernández‐Losa, A. Derouiche, et al.
genesis (2023) Vol. 62, Iss. 1
Closed Access | Times Cited: 4
Unveiling novel insights in prostate cancer through single-cell RNA sequencing
Wenyue Yu, Chun Wang, Zhiqun Shang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
Mariangela Calabrese, Isabella Saporita, Fabio Turco, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 78-78
Open Access | Times Cited: 4
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators
Yuankang Feng, Yu Zhang, Hao Li, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 8
Open Access | Times Cited: 1
Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells
Emily Archer Goode, Margarita Orozco‐Moreno, Kirsty Hodgson, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 2953-2953
Open Access | Times Cited: 1
Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC
Ren Liu, Zhihao Zou, Zhengrong Zhang, et al.
Cancer Letters (2024) Vol. 605, pp. 217286-217286
Closed Access | Times Cited: 1
Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
Taraswi Mitra Ghosh, Jason White, Joshua Davis, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 9
Deregulated miRNAs in enzalutamide resistant prostate cancer: A comprehensive review of key molecular alterations and clinical outcomes
Inês Ferreira Dias Tavares, Mariana Morais, Francisca Dias, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1879, Iss. 2, pp. 189067-189067
Closed Access | Times Cited: 3
Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy
Fábio Montico, Celina de Almeida Lamas, Isabela Maria Urra Rossetto, et al.
Journal of Molecular Histology (2023) Vol. 54, Iss. 4, pp. 379-403
Closed Access | Times Cited: 3
Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer
Yun Peng, Yuxuan Song, Haitao Wang
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 5

Scroll to top